Im­mutep touts mid-stage da­ta for LAG-3 drug in first-line NSCLC, fi­nal­iz­ing plans for PhI­II test: #ES­MO23

MADRID — Im­mutep un­veiled ad­di­tion­al da­ta at ES­MO from a Phase II tri­al study­ing a LAG-3 drug de­signed to help cer­tain non-small cell lung can­cer pa­tients po­ten­tial­ly do away with chemother­a­py.

The biotech is fi­nal­iz­ing plans for a Phase III tri­al for the first half of 2024 based on these re­sults and af­ter rais­ing $53 mil­lion in June. The Phase II TAC­TI-002 study com­bines efti­lag­i­mod al­pha — efti for short — with Mer­ck’s Keytru­da in first-line un­re­sectable or metasta­t­ic NSCLC.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER